30.09.2022 • NewsArkemarenewable

Arkema Ups Expansion Plans for Pebax Elastomers

Arkema has boosted its previously announced expansion plans for Pebax elastomer at its Serquigny site in France. The company will now increase capacity by 40% rather than the 25% it announced in January this year.

The project will be undertaken in two separate phases. The first will raise output by 15% in the first quarter of 2023, then by a further 25% starting in the third quarter of next year.

In addition to the French expansion, Arkema said it is currently assessing further investment opportunities, including in Asia, in order to support the growth of its global customers in the sports, consumer electronics, medical and industrial markets. Applications range from running shoes and ski boots to catheters and to flexible device screens.

Arkema cited particularly strong growth for its bio-based Pebax grade called Rnew that is derived from renewable castor beans and can be fully recycled.

“We are very excited to announce this acceleration of our Pebax elastomer capacity increase. Demand continues to grow, especially for our bio-based Pebax Rnew range”, said Erwoan Pezron, senior vice president of Arkema’s high-performance polymers business. “There is no compromise between high performance and sustainability. Our customers demand both.”

Author: Elaine Burridge, Freelance Author

(c) Arkema
(c) Arkema

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis